Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 5/20 | 0.53 |
| ▸ | ANPEP | P15144 | 4/20 | 0.53 |
| ▸ | ACP3 | P15309 | 4/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074290 | 0.79 | IDO1 (0.43) | LAP3ANPEPACP3IDO1LMNA | |
| SCHEMBL11295162 | 0.75 | ALDH1A1 (0.58) | LAP3ANPEPACP3LMNATSHR | |
| SCHEMBL2934111 | 0.74 | SLC6A4 (0.46) | LAP3CYP3A4CYP2D6 | |
| SCHEMBL7158870 | 0.72 | LAP3 (0.64) | LAP3ANPEPACP3ERAP1ERAP2 | |
| SCHEMBL7742563 | 0.72 | LAP3 (0.64) | LAP3ANPEPACP3ERAP1ERAP2 | |
| SCHEMBL10714585 | 0.71 | LAP3 (0.62) | LAP3ANPEPACP3ERAP1ERAP2 | |
| SCHEMBL27481841 | 0.71 | LAP3 (0.62) | LAP3ANPEPACP3ERAP1ERAP2 | |
| SCHEMBL2375608 | 0.69 | LAP3 (1.00) | LAP3ANPEPACP3ERAP1ERAP2 | |
| SCHEMBL7529859 | 0.69 | LAP3 (0.78) | LAP3ANPEPACP3ERAP1ERAP2 | |
| SCHEMBL10710542 | 0.69 | LAP3 (0.60) | LAP3ANPEPACP3ERAP1ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5593659-A | IN THE FORM OF PHYSIOLOGICALLY ACCEPTABLE SALTS; MEDICAL DIAGNOSIS; WATER SOLUBLE, NONTOXIC | CONCAT, LTD. (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0513000-B1 | MRI IMAGE ENHANCEMENT OF BONE AND RELATED TISSUE USING COMPLEXES OF PARAMAGNETIC CATIONS AND POLYPHOSPHONATE LIGANDS | CONCAT LTD (US) | 1996-07-31 | — | — | EP | disclosed |
| US-5380515-A | CONTRAST | CONCAT, LTD. (US) | 1995-01-10 | — | — | US | disclosed |
| US-5236695-A | Medical diagnosis | CONCAT, LTD. (US) | 1993-08-17 | — | — | US | disclosed |
| EP-0513000-A1 | MRI IMAGE ENHANCEMENT OF BONE AND RELATED TISSUE USING COMPLEXES OF PARAMAGNETIC CATIONS AND POLYPHOSPHONATE LIGANDS. | CONCAT LTD (US) | 1992-11-19 | — | — | EP | disclosed |
| EP-0513000-A4 | MRI IMAGE ENHANCEMENT OF BONE AND RELATED TISSUE USING COMPLEXES OF PARAMAGNETIC CATIONS AND POLYPHOSPHONATE LIGANDS. | CONCAT LTD (US) | 1992-09-01 | — | — | EP | disclosed |
| WO-1991007911-A1 | MRI IMAGE ENHANCEMENT OF BONE AND RELATED TISSUE USING COMPLEXES OF PARAMAGNETIC CATIONS AND POLYPHOSPHONATE LIGANDS | CONCAT LTD. (US) | 1991-06-13 | — | — | WO | disclosed |